MYCN
Summary: This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2014].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MYCN proto-oncogene, bHLH transcription factor | MIM:164840 | Ensembl:ENSG00000134323 | HGNC:HGNC:7559 | PA31359 | 2p24.3 |
Gene Categories:
CLINICALLY ACTIONABLEGO terms in MYCN
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IDA | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | NAS | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | IDA | GO:0001077 | transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding |
| MF | TAS | GO:0003677 | DNA binding |
| MF | TAS | GO:0003700 | DNA-binding transcription factor activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IPI | GO:0019900 | kinase binding |
| MF | IEA | GO:0046983 | protein dimerization activity |
| CC | TAS | GO:0000785 | chromatin |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005730 | nucleolus |
| BP | IEA | GO:0001502 | cartilage condensation |
| BP | IEA | GO:0002053 | positive regulation of mesenchymal cell proliferation |
| BP | TAS | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0006366 | transcription by RNA polymerase II |
| BP | IDA | GO:0010628 | positive regulation of gene expression |
| BP | IDA | GO:0010629 | negative regulation of gene expression |
| BP | IEA | GO:0010942 | positive regulation of cell death |
| BP | IEA | GO:0030324 | lung development |
| BP | IEA | GO:0042733 | embryonic digit morphogenesis |
| BP | IEA | GO:0045607 | regulation of inner ear auditory receptor cell differentiation |
| BP | IMP | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | IDA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0048704 | embryonic skeletal system morphogenesis |
| BP | IEA | GO:0048712 | negative regulation of astrocyte differentiation |
| BP | IEA | GO:0048754 | branching morphogenesis of an epithelial tube |
| BP | IC | GO:1903800 | positive regulation of production of miRNAs involved in gene silencing by miRNA |
| BP | IEA | GO:2000378 | negative regulation of reactive oxygen species metabolic process |
Gene expression in normal tissue: MYCN
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MYCN
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| kegg | hsa05202 | Transcriptional misregulation in cancer - Homo sapiens (human) |
| wikipathways | WP2004 | miR-targeted genes in lymphocytes - TarBase |
| wikipathways | WP3651 | Pathways Affected in Adenoid Cystic Carcinoma |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD536 | PLX-4720 | 1 |
| iGMDRD178 | MG-132 | 1 |
| iGMDRD945 | ML214 | 2 |
| iGMDRD39 | Pyrimethamine | 1 |
| iGMDRD512 | nutlin 3 | 6 |
| iGMDRD382 | CEP-701 | 1 |
| iGMDRD589 | HG-5-113-01 | 1 |
| iGMDRD405 | PIK-75 | 3 |
| iGMDRD594 | AZD-8055 | 1 |
| iGMDRD456 | Crizotinib | 1 |
| iGMDRD560 | MK-2206 | 3 |
| iGMDRD150 | RITA | 9 |
| iGMDRD329 | Merck60 | 7 |
| iGMDRD286 | Nsc 632839 | 2 |
| iGMDRD400 | A-443654 | 1 |
| iGMDRD42 | Vorinostat | 1 |
| iGMDRD421 | AZD7762 | 1 |
| iGMDRD300 | Tozasertib | 9 |
| iGMDRD505 | Pevonedistat | 1 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD1006 | SMO inhibitor | 1 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD481 | Dactolisib | 1 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD503 | CMK | 1 |
| iGMDRD289 | Parthenolide | 4 |
| iGMDRD748 | PHA-665752 | 2 |
| iGMDRD152 | 179324-69-7 | 3 |
| iGMDRD936 | JW-7-52-1 | 1 |
| iGMDRD608 | Refametinib | 1 |
| iGMDRD634 | SCHEMBL2608041 | 4 |
| iGMDRD673 | LSM-1215 | 1 |
| iGMDRD378 | ZM-447439 | 1 |
| iGMDRD409 | Saracatinib | 1 |
| iGMDRD1034 | WZ3105 | 1 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD129 | SB-216763 | 1 |
| iGMDRD781 | Sirolimus | 1 |
| iGMDRD484 | Pluripotin | 3 |
| iGMDRD629 | Cbl0137 | 1 |
| iGMDRD462 | OSI-906 (Linsitinib) | 1 |
| iGMDRD144 | NSC95397 | 5 |
| iGMDRD562 | Navitoclax | 1 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD399 | Selumetinib | 2 |
| iGMDRD133 | Lapatinib | 1 |
| iGMDRD451 | Serdemetan | 3 |
| iGMDRD41 | Imatinib | 1 |
| iGMDRD131 | Erlotinib | 2 |
| iGMDRD190 | Nilotinib | 1 |
| iGMDRD431 | NU-7441 | 1 |
| iGMDRD992 | QL-VIII-58 | 1 |
| iGMDRD134 | Sorafenib | 1 |
| iGMDRD568 | SCHEMBL15005512 | 1 |
| iGMDRD491 | TAE-684 | 1 |
| iGMDRD309 | 17AAG | 1 |
| iGMDRD593 | CX-5461 | 1 |
| iGMDRD440 | Nutlin-3A | 1 |
| iGMDRD318 | PAC-1 | 1 |
| iGMDRD284 | Palbociclib | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MYCN
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.